Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biomolecules|January 21, 2022
Androgen Receptor as an Emerging Feasible Biomarker for Breast CancerChan-Ping You, Man-Hong Leung, Wai-Chung Tsang, et al.
International Journal of Molecular Sciences|December 11, 2022
Modulating the Activity of Androgen Receptor for Treating Breast CancerChan-Ping You, Ho Tsoi, Ellen P S Man, et al.
Cancers|March 10, 2022
Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast CancerHo Tsoi, Chan-Ping You, Man-Hong Leung, et al.
Life (Basel, Switzerland)|August 29, 2024
Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93Ho Tsoi, Ling Shi, Man-Hong Leung, et al.
Life (Basel, Switzerland)|January 21, 2022
Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast CancerHo Tsoi, Ling Shi, Man-Hong Leung, et al.
Cancers|March 1, 2020
A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2Man-Hong Leung, Ho Tsoi, Chun Gong, et al.
International Journal of Molecular Sciences|October 27, 2022
Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast CancerHo Tsoi, Wai-Chung Tsang, Ellen P S Man, et al.
The Journal of Pathology|August 9, 2023
Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancerHo Tsoi, Johann Lok, Ellen Ps Man, et al.
Cancers|May 16, 2023
SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast CancerHo Tsoi, Nicholas Nok-Ching Fung, Ellen P S Man, et al.
Frontiers in Oncology|February 7, 2013
FOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1cAndy K Y Lam, Adaline W L Ngan, Man-Hong Leung, et al.
Pageof 2